论文部分内容阅读
拜新同是硝苯吡啶控释片,为钙离子拮抗剂,其作用持续时间长,不良反应较少。笔者总结30例轻、中度原发性高血压患者在拜新同治疗前后血压及其它有关指标,旨在进一步了解拜新同的降压疗效及不良反应。一、对象与方法 (一)病例选择:选择门诊患者30例,高血压诊断标准及分期采用1993年WHO/ISH联合提出的诊断标准,经病史、体检和实验室检查排除继发性高血压、恶性及急进型高血压。30例患者中男17例,女13例,年龄34～65岁,平均50.5±8.9岁,
Thanks to the new with the nifedipine controlled release tablets, calcium antagonists, the role of long duration, fewer adverse reactions. The author summarizes 30 cases of mild to moderate essential hypertension patients before and after treatment of new blood pressure and other relevant indicators, aims to further understand the new anti-step-down efficacy and adverse reactions. First, the object and method (A) Case Selection: 30 outpatients were selected, diagnostic criteria and staging of hypertension using 1993 WHO / ISH jointly proposed diagnostic criteria, medical history, physical examination and laboratory tests to exclude secondary hypertension, Malignant and radical type of hypertension. Thirty patients were 17 males and 13 females, aged from 34 to 65 years, with an average of 50.5 ± 8.9 years.